Acquired hemophilia A: Diagnosis, aetiology, clinical spectrum and treatment options

作者：Shetty Shrimati^*; Bhave M****i; Ghosh Kanjaksha

来源：Autoimmunity Reviews, 2011, 10(6): 311-316.

DOI：10.1016/j.autrev.2010.11.005

• Acquired hemophilia A
• Autoantibodies
• Immunosuppressive therapy
• Factor VIII
• Inhibitors

Acquired hemophilia A (AHA) is a rare disorder with an incidence of approximately 1 per million/year with a high mortality rate of more than 20%. The disease occurs due to autoantibodies against coagulation factor VIII (FVIII) which neutralize its procoagulant function and result in severe, often life-threatening bleeding. The antibodies arise in individuals with no prior history of hemophilia A. AHA may be associated with pregnancy, autoimmune diseases, malignancy, infections or medication and occurs most commonly in the elderly. Approximately 50% of the patients remain idiopathic with no known underlying pathological condition. Clinical manifestations include spontaneous hemorrhages into the skin, muscles or soft tissues or excessive bleeding during surgery. Hemarthrosis which is the hallmark of congenital severe hemophilia A seldom occurs in AHA. The diagnosis of AHA is based on the isolated prolongation of activated partial thromboplastin time (APTT) which does not normalize after the addition of normal plasma along with reduced FVIII levels. The treatment involves two aspects eradication of antibodies and maintaining effective hemostasis during a bleeding episode. The protocols for eradication of antibodies include immunoadsorption, immunosuppression or immune tolerance induction (ITI). The treatment of acute bleeding episodes involves use of different bypassing agents like recombinant activated factor Vila (rFVIIa, NovoSeven (R)) and activated prothrombin complex concentrate (aPCC, (FEIBA (R)) in case of patients with high titer inhibitors or with antifibrinolytics, 1-deamino-8-D-arginine vasopressin (DDAVP) or FVIII concentrates in low titer inhibitor patients. The anti CD20 monoclonal antibody, rituximab, has shown very good results either singly or in combination with immunosuppressive regimens in patients who do not respond to standard immunosuppressors. The present review summarizes the diagnostic, aetiological, clinical and treatment aspects of AHA focusing on the recent advances in this area.

• 出版日期2011-4
• 单位西北大学